Alimentary pharmacology & therapeutics · 2026
Eosinophilic Oesophagitis Beyond the Oesophagus: High Prevalence of Chronic Rhinosinusitis-Type Symptoms and Their Impact on Symptom Severity in Swiss EoE Cohort Study Patients.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Aidan Gebhardt, Andrea Kreienbühl, Thomas Greuter, Christoph Schlag, Simon Nennstiel, Catherine Saner, Jean-Benoit Rossel, Tina Mauthe, Meerwein Christian M, Alain Schoepfer, Soyka Michael B, Alex Straumann, Luc Biedermann, Swiss EoE Cohort Study Group
Аннотация
BACKGROUND: Both eosinophilic oesophagitis (EoE) and chronic rhinosinusitis (CRS) are type 2 inflammatory conditions sharing pathogenic mechanisms, therapeutic responses and atopic associations. Data on the prevalence of CRS in EoE patients is missing.
AIMS: Our aim was to assess the prevalence of CRS-type symptoms in EoE patients, the quality of life and shared characteristics of patients with both diseases.
METHODS: We assessed the point prevalence of CRS in Swiss Eosinophilic Esophagitis Cohort Study patients using a validated screening questionnaire comprising four symptom-based diagnostic criteria. CRS was defined based on symptoms only (definition A) and including self-reported CRS diagnosis by a physician (definition B). Point prevalence was tested against population prevalence using two-sided binomial tests. Secondary outcomes were compared between patients with and without CRS. Multivariable logistic regression models were built to adjust for confounders.
RESULTS: 211 patients (54%) answered our questionnaire. Prevalence of CRS-type symptoms was 21.8% (definition A) or 25.1% (definition B), compared to 8.71% in the general population (p < 0.0001). CRS status was associated with increased EoE symptom severity. This association persisted after adjustment in multivariable logistic models, most consistently under definition A. 25% reported that their CRS symptoms were more debilitating than their EoE symptoms.
CONCLUSION: CRS-type symptoms are two- to three times more prevalent in EoE patients than in the general population and substantially impact quality of life. Our findings indicate that CRS may be under-diagnosed in EoE and support routine CRS screening in EoE patients and cross-speciality collaboration, particularly as both conditions benefit from therapeutic strategies targeting type 2 inflammation.
AIMS: Our aim was to assess the prevalence of CRS-type symptoms in EoE patients, the quality of life and shared characteristics of patients with both diseases.
METHODS: We assessed the point prevalence of CRS in Swiss Eosinophilic Esophagitis Cohort Study patients using a validated screening questionnaire comprising four symptom-based diagnostic criteria. CRS was defined based on symptoms only (definition A) and including self-reported CRS diagnosis by a physician (definition B). Point prevalence was tested against population prevalence using two-sided binomial tests. Secondary outcomes were compared between patients with and without CRS. Multivariable logistic regression models were built to adjust for confounders.
RESULTS: 211 patients (54%) answered our questionnaire. Prevalence of CRS-type symptoms was 21.8% (definition A) or 25.1% (definition B), compared to 8.71% in the general population (p < 0.0001). CRS status was associated with increased EoE symptom severity. This association persisted after adjustment in multivariable logistic models, most consistently under definition A. 25% reported that their CRS symptoms were more debilitating than their EoE symptoms.
CONCLUSION: CRS-type symptoms are two- to three times more prevalent in EoE patients than in the general population and substantially impact quality of life. Our findings indicate that CRS may be under-diagnosed in EoE and support routine CRS screening in EoE patients and cross-speciality collaboration, particularly as both conditions benefit from therapeutic strategies targeting type 2 inflammation.